The usefulness of the platelet function analyser (PFA-100) in screening for underlying bleeding disorders in women with menorrhagia

References

• Bradlow J, Coulter A, Brooks P. Patterns of referral. Health Services Research Unit, Oxford 1992
   Google Scholar
• Cariappa R, Wilhite T R, Parvin C A, Luchtman-Jones L. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. Journal of Pediatric Hematology/Oncology 2003; 25: 474–479
   PubMed Web of Science ®Google Scholar
• Dilley A, Drews C, Miller C, Lally C, Austin H, Ramaswamy D, et al. von Willebrand disease and other inherited bleeding disorders in women diagnosed with menorrhagia. Obstetrics and Gynecology 2001; 97: 630–636
   PubMed Web of Science ®Google Scholar
• Eugster M, Reinhart W H. The influence of the haematocrit on primary haemostasis in vitro. Thrombosis and Haemostasis 2005; 94: 1213–1218
   PubMed Web of Science ®Google Scholar
• Favaloro E J. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease. Blood Reviews 1999a; 13: 185–204
   PubMed Web of Science ®Google Scholar
• Favaloro E J, Facey D, Henniker A. Use of a novel platelet function analyzer (PFA-100) with high sensitivity to disturbances in von Willebrand factor to screen von Willebrand's disease and other disorders. American Journal of Hematology 1999b; 62: 165–174
   PubMed Web of Science ®Google Scholar
• Favaloro E J. The utility of the PFA-100 in the identification of von Willebrand disease: a concise review. Seminars in Thrombosis and Hemostasis 2006; 32: 537–545
   PubMed Web of Science ®Google Scholar
• Feuring M, Christ M, Roell A, Schueller P, Losel R, Dempfle C E, et al. Alterations in platelet function during the ovarian cycle. Blood Coagulation and Fibrinolysis 2002; 13: 443–447
   PubMed Web of Science ®Google Scholar
• Franchini M. The platelet function analyzer (PFA-100): an update on its clinical use. Clinical Laboratory 2005; 51: 367–372
   PubMed Web of Science ®Google Scholar
• Francis J, Francis D, Larson L, Helms E, Garcia M. Can the platelet function analyzer (PFA)- 100 test substitute for the template bleeding time in routine clinical practice?. Platelets 1999; 10: 132–136
   PubMed Web of Science ®Google Scholar
• Gill J C, Endres-Brooks J, Bauer P J, Marks W J, Jr, Montgomery R R. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691–1695
   PubMed Web of Science ®Google Scholar
• Goldenberg N A, Jacobson L, Manco-Johnson M J. Brief communication: duration of platelet dysfunction after a 7-day course of Ibuprofen. Annals of Internal Medicine 2005; 142: 506–509
   PubMed Web of Science ®Google Scholar
• Harrison P, Robinson M, Liesner R, Khair K, Cohen H, Mackie I, et al. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clinical and Laboratory Haematology 2002; 24: 225–232
   PubMedGoogle Scholar
• Haubelt H, Anders C, Vogt A, Hoerdt P, Seyfert U T, Hellstern P. Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals. British Journal of Haematology 2005; 130: 759–767
   PubMed Web of Science ®Google Scholar
• Hayward C P, Harrison P, Cattaneo M, Ortel T L, Rao A K. The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. 2006. Platelet function analyzer (PFA)- 100 closure time in the evaluation of platelet disorders and platelet function. Journal of Thrombosis and Haemostasis, 4: 312–319
   PubMedGoogle Scholar
• James A H, Lukes A S, Brancazio L R, Thames E, Ortel T L. Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia. American Journal of Obstetrics and Gynecology 2004; 191: 449–455
   PubMed Web of Science ®Google Scholar
• Kadir R A, Economides D L, Sabin C A, Owens D, Lee C A. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998; 351: 485–489
   PubMed Web of Science ®Google Scholar
• Karger R, Donner-Banzhoff N, Müller H H, Kretschmer V, Hunink M. Diagnostic performance of the platelet function analyzer (PFA-100) for the detection of disorders of primary haemostasis in patients with a bleeding history – a systematic review and meta-analysis. Platelets 2007; 18: 249–260
   PubMed Web of Science ®Google Scholar
• Konrad C J, Schuepfer G K, Gerber H, Rukwied R, Schmelz M, Schley M. Duration of effects of aspirin on platelet function in healthy volunteers: an analysis using the PFA-100. Journal of Clinical Anesthesia 2006; 18: 12–17
   PubMed Web of Science ®Google Scholar
• Koscielny J, Ziemer S, Radtke H, Schmutzler M, Kiesewtter H, Salama A, et al. Preoperative identification of patients with impaired (primary) hemostasis. A practical concept [in German] Hamostaseologie 2007; 27: 177–184
   PubMedGoogle Scholar
• Marshall P W, Williams A J, Dixon R M, Growcott J W, Warburton S, Armstrong J, et al. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. British Journal of Clinical Pharmacology 1997; 44: 151–155
   PubMed Web of Science ®Google Scholar
• Michelson A D, Frelinger A L, 3rd, Furman M I. Current options in platelet function testing. American Journal of Cardiology 2006; 98: 4N–10N
   PubMed Web of Science ®Google Scholar
• Mischke R, Keidel A. Influence of platelet count, acetylsalicylic acid, von Willebrand's disease, coagulopathies and haematocrit on results obtained using a platelet function analyser in dogs. Veterinary Journal 2003; 165: 43–52
   PubMed Web of Science ®Google Scholar
• Nitu-Whalley I C, Lee C A, Griffioen A, Jenkins P V, Pasi K J. Type 1 von Willebrand disease – a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. British Journal of Haematology 2000; 108: 259–264
   PubMed Web of Science ®Google Scholar
• Ortel T L, James A H, Thames E H, Moore K D, Greenberg C S. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thrombosis and Haemostasis 2000; 84: 93–97
   PubMed Web of Science ®Google Scholar
• Posan E, McBane R D, Grill D E, Motsko C L, Nichols W L. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thrombosis and Haemostasis 2003; 90: 483–490
   PubMed Web of Science ®Google Scholar
• Philipp C S, Faiz A, Dowling N, Dilley A, Michaels L A, Ayers C, et al. Age and the prevalence of bleeding disorders in women with menorrhagia. Obstetrics and Gynecology 2005a; 105: 61–66
   PubMed Web of Science ®Google Scholar
• Philipp C S, Miller C H, Faiz A, Dilley A, Michaels L A, Ayers C, et al. Screening women with menorrhagia for underlying bleeding disorders: the utility of the platelet function analyser and bleeding time. Haemophilia 2005b; 11: 497–503
   PubMed Web of Science ®Google Scholar
• Reber G, Boehlen F, Fontana P. Study of primary hemostasis in vitro with Platelet Function Analyzer (PFA-100). Revue Médicale de la Suisse Romande 2003; 123: 491–494
   PubMedGoogle Scholar
• Rees M. Menorrhagia. British Medical Journal 1987; 294: 759–762
   PubMed Web of Science ®Google Scholar
• Reid P C. Assessment of menstrual blood loss using a pictorial chart: a validation study. British Journal of Obstetrics and Gynaecology 2000; 107: 320–322
   Google Scholar
• Riddell A F, Jenkins V P, Nitu-Whalley I C, McCraw A H, Lee C A, Brown S A. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with ristocetin cofactor assay. British Journal of Haematology 2002; 116: 187–192
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand disease. Blood 1987; 69: 454–459
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Castaman G, Tosetto A. von Willebrand factor antigen is less sensitive than ristocetin cofactor for the diagnosis of type 1 von Willebrand disease- results based on an epidemiological investigation. Thrombosis and Haemostasis 1990; 64: 349–352
   PubMedGoogle Scholar
• Rose E H, Aledort L M. Nasal spray desmopressin (DDAVP) for mild hemophilia and von Willebrand disease. Annals of Internal Medicine 1991; 114: 563–568
   PubMed Web of Science ®Google Scholar
• Royal College of General Practitioners. Office of Population Censuses and Surveys, Department of Health and Social Security. Morbidity statistics from general practice. Third National Study 1981–1982. Series MBS No.1. HMSO, London 1986
   Google Scholar
• Sadler J E. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thrombosis and Haemostasis 1994; 71: 520–525
   PubMed Web of Science ®Google Scholar
• Shankar M, Lee C A, Sabin C A, Economides D L, Kadir R A. Von Willebrand disease in women with menorrhagia: a systematic review. British Journal of Obstetrics and Gynaecology 2004; 111: 734–740
   Google Scholar
• Werner E J, Broxson E H, Tucker E L, Giroux D S, Shults J, Abshire T C. Prevalence of von Willebrand disease in children: a multiethnic study. Journal of Pediatrics 1993; 123: 893–898
   PubMed Web of Science ®Google Scholar